This article is more than 5 years old. Information may no longer be current.

Proton beam radiotherapy of uveal melanoma yields high rate of tumor control

Eur J Ophthalmol. 2009;19(4): 654-660.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Irradiation of uveal tumors with a proton beam effectively controls tumor growth in the long term and results in high survival and eye retention rates, according to a study.

Out of 368 cases treated for intraocular melanoma with a proton beam, 8.4% had a tumor relapse. Median time to recurrence was 46 months after radiotherapy.

Enucleation was performed in 45 eyes (11.7%) at a median time of 49 months after radiotherapy; of these 45 eyes, 29 were enucleated for tumor relapse.

In univariate regression analysis, tumor height and diameter were identified as primary factors for enucleation. Multivariate analysis revealed five risk factors that predicted whether a patient might suffer a relapse: macula distance, optic disc distance, tumor height, maximum diameter and age.

Patients in the study were enrolled from a set of patients in Italy who were treated at Centre Lacassagne Cyclotron Biomedical of Nice, France, between 1991 and 2006.